Paul B. Chapman

43.7k citations
233 papers · 15.5k · 6 hit papers · h-index 57

Impact in

  • Oncology top 0.1%
    • Cancer Immunotherapy and Biomarkers
    • Cutaneous Melanoma Detection and Management
    • CAR-T cell therapy research
  • Immunology top 0.5%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction

Papers in

    • Melanoma and MAPK Pathways 98
    • Glycosylation and Glycoproteins Research 18
    • Cutaneous Melanoma Detection and Management 54
    • Cancer Immunotherapy and Biomarkers 44
    • CAR-T cell therapy research 41

Paul B. Chapman

226 papers receiving 15.2k citations

Paul B. Chapman's Hit Papers

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center 2015 · 808 citations
8080+9+18Years since publication50010001.5k2.0k2.5k

Peers

Paul B. Chapman
Comparison fields: 5 of 148
  • Oncology 9.1k
  • Immunology 4.1k
  • Molecular Biology 8.5k
  • Cancer Research 1.5k
  • Ophthalmology 784
Replace Axel Hauschild with:
Axel Hauschild Germany
Adil Daud United States
Richard Kefford Australia
Michele Maio Italy
Michael A. Davies United States
Paolo A. Ascierto Italy
Douglas B. Johnson United States
Klaus J. Busam United States
Ulrich Keilholz Germany
Vernon K. Sondak United States
Paul B. Chapman relative to Axel Hauschild Germany Axel Hauschild's profile →
Citations per field
00.5×1.6×
Axel Hauschild · 1×
Citations per year

Countries citing papers authored by Paul B. Chapman

Since Specialization
Citations

This map shows the geographic impact of Paul B. Chapman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul B. Chapman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul B. Chapman more than expected).

Fields of papers citing papers by Paul B. Chapman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul B. Chapman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul B. Chapman. The network helps show where Paul B. Chapman may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul B. Chapman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul B. Chapman Line = papers co-authored together Paul B. Chapman links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 233 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Hit paper breakdown →
20102608
2
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Hit paper breakdown →
20121378
3
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Hit paper breakdown →
2015808
4
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
Hit paper breakdown →
1999542
5
Evolutionary dynamics of cancer in response to targeted combination therapy
Hit paper breakdown →
2013433
6 2010349
7
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
Hit paper breakdown →
2010344
8 2003228
9 2005228
10 2014219
11 2004213
12 2010199
13 2017189
14 1987183
15 2012176
16 1993175
17 2005168
18 2009163
19 2010156
20 2008146

About Paul B. Chapman

Paul B. Chapman is a scholar working on Molecular Biology, Oncology, Immunology, Radiology, Nuclear Medicine and Imaging and Computational Theory and Mathematics, having authored 233 papers that have together received 15.5k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (98 papers), Cutaneous Melanoma Detection and Management (54 papers), Immunotherapy and Immune Responses (50 papers), Cancer Immunotherapy and Biomarkers (44 papers), CAR-T cell therapy research (41 papers), Monoclonal and Polyclonal Antibodies Research (29 papers), Computational Drug Discovery Methods (26 papers) and Glycosylation and Glycoproteins Research (18 papers). The work is most often cited by research in Oncology (9.1k citations), Immunology (4.1k citations), Molecular Biology (8.5k citations), Cancer Research (1.5k citations) and Ophthalmology (784 citations). Paul B. Chapman has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Katherine S. Panageas, Keith T. Flaherty, Antoni Ribas, Jedd D. Wolchok, Grant A. McArthur, Jeffrey A. Sosman, Alan N. Houghton, K. B. Nolop, Igor Puzanov and Joseph F. Grippo. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer, Melanoma Research and American Society of Clinical Oncology Educational Book.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact